[Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] [Tag] I've kept quiet for a while now because the whole debate over Gleason 9-10 disease seems dated. My hope is that we can reclassify molecular subtypes of prostate cancer better to stratify who may benefit more with surgery or radiation.